Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Cancer Research|February 8, 2020
<i>UBR5</i> Is Coamplified with <i>MYC</i> in Breast Tumors and Encodes an Ubiquitin Ligase That Limits MYC-Dependent ApoptosisXi Qiao, Ying Liu, Maria Llamazares Prada, et al.
Science Advances|October 30, 2024
Ex vivo modeling of precision immuno-oncology responses in lung cancerBassel Alsaed, Johannes Smolander, Hanna Laitinen, et al.
Cancer Research Communications|February 4, 2026
Functionally characterizing the renal cell carcinoma tumor immune microenvironment via patient-derived ex vivo modelsNeja Sirc, Johannes Smolander, Anita N Kumari, et al.
Cancer Research|February 12, 2022
A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non-Small Cell Lung CancerJieun Son, Jaebong Jang, Tyler S Beyett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung CancerBiagio Ricciuti, Jieun Son, Jeffrey J Okoro, et al.
Nature Communications|February 22, 2019
Publisher Correction: Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapyHeidi M Haikala, Johanna M Anttila, Elsa Marques, et al.
Nature Communications|January 2, 2025
Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironmentBassel Alsaed, Linh Lin, Jieun Son, et al.
Nature Communications|February 8, 2019
Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapyHeidi M Haikala, Johanna M Anttila, Elsa Marques, et al.
Cell Reports Methods|June 4, 2026
Precision tumor-on-chip for personalized assessment of drug efficacy and immune cell deliveryElena Kremneva, Johannes Smolander, Mimosa Peltokangas, et al.
Cancer Research|September 22, 2021
EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXdHeidi M Haikala, Timothy Lopez, Jens Köhler, et al.
Pageof 3